Sunitinib is a multitargeted tyrosine kinase inhibitor approved for gastrointestinal stromal
tumor (GIST), advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors …

Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes
that are involved in multiple cellular processes. Currently, multiple oral TKIs have been …

Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide
polymorphisms (SNPs) in PK candidate genes have been associated with the efficacy and …

Sunitinib is a small molecule inhibitor of multiple receptor tyrosine kinases such as platelet
derived growth factor receptor, vascular endothelial growth factor receptor, kit receptor and …

BACKGROUND: Sunitinib malate is a novel oral multitargeted tyrosine kinase inhibitor with
antitumor and antiangiogenic activities. Only mass spectrometry detection is currently …

An original method based on liquid chromatography with single quadrupole electrospray
ionization mass spectrometry was developed for the determination of sunitinib in human …

Clear-cell renal carcinoma is the most common cancer of the kidney [1]. Up to 30% of
patients with renal-cell carcinoma present with metastatic disease [2, 3] and recurrence …

Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved for the treatment of
advanced renal cell carcinoma, imatinib-refractory gastrointestinal stromal tumor, and …

Purpose To develop a population pharmacokinetic (PK) model for HM781-36 (poziotinib)
and its metabolites in cancer patients. Methods Blood samples were collected from three …

3561 Background: Sunitinib is an oral multitargeted tyrosine kinase inhibitor of VEGF, PDGF,
c-KIT, and flt-3 receptors. This study was conducted to define the dose limiting toxicities …